Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNORHO for prevention of RhD isoimmunization in RhD-negative pregnant women
2020-003570-49Phase 3Completed
- Sponsor
- Kedrion Biopharma
- Start
- Nov 2020
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rho(d) immune globulin in RhD alloimmunization, sponsored by Kedrion Biopharma. Primary endpoint: Incidence of anti-D antibodies at 24 weeks after last treatment. Started Nov 2020; status: completed.
02
Drugs
rho(d) immune globulin
03
Conditions
RhD alloimmunization
Beyond the preview
Go deeper on 2020-003570-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003570-49.